A molecular analysis of human aldolase B genes in two newborn infants and a 4-year-old child with hereditary fructose intolerance, the offspring of a consanguineous union, has identified the novel mutation Ala$$( Val in homozygous form. This mutation was also detected independently in two other affected individuals who were compound heterozygotes for the prevalent aldolase B allele, Ala"%* Pro, indicating that the mutation causes aldolase B deficiency. To test for the effect of the mutation, catalytically active wild-type human aldolase B and the Val$$( variant enzyme were expressed in Escherichia coli. The specific activities of the wild-type recombinant enzyme were 4.8 units\mg and 4.5 units\mg towards fructose 1,6-bisphosphate (FBP) and fructose 1-phosphate (F-1-P) as substrates with Michaelis constants of 4 µM and 2.4 mM respectively. The specific activities of purified tetrameric Val$$( aldolase B, which affects an invariant residue in the C-terminal region, were 4.2 units\mg and 2.6 units\mg towards FBP and F-1-P as substrates respectively ; the corresponding Michaelis constants were 22 µM and 24 mM. The FBP-to-F-1-P substrate activity ratios were 0.98 and 1.63 for
INTRODUCTION
Inherited deficiency of aldolase B (fructose-1,6-bisphosphate aldolase, EC 4.1.2.13) in the liver, kidney and intestine is associated with the human metabolic disorder hereditary fructose intolerance (HFI) [1] . After consuming fructose and its cogeners in the diet, affected individuals suffer abdominal symptoms associated with hypoglycaemia and metabolic acidosis [2] . Newborn infants, who might be given the noxious sugars indiscriminately, are most vulnerable to their effects. As a result, potentially fatal hepatic and renal injury can occur [3, 4] . Provided that dietary exclusion of fructose and related sugars is instituted promptly, the severe manifestations of the disorder can be prevented and the infant can survive to healthy adulthood [5] . Metabolic studies of patients with HFI show that infusions of -fructose rapidly inhibit hepatic glycogenolysis and gluconeogenesis, causing hypoglycaemia and lactic acidosis [1] . These disturbances are attributed to the accumulation of undegraded fructose 1-phosphate (F-1-P) in the affected tissues, which inhibits fructose-1,6-bisphosphate aldolase activity in the gluconeogenic pathway : in a milieu that is depleted of free inorganic phosphate, glycogen phosphorylase is also inhibited [1, 6] .
Three genetically distinct isoenzymes of fructaldolase (aldolases A, B and C) are found in vertebrates [7] . The enzymes show differential activities towards the two substrates F-1-P and Abbreviations used : F-1-P, fructose 1-phosphate ; FBP, fructose 1,6-bisphosphate ; HFI, hereditary fructose intolerance ; IPTG, isopropyl β-Dthiogalactoside. 1 These authors contributed equally to this study. 2 Present address : Molecular Medicine Unit, Level 6 Clinical Sciences Building, St James's University Hospital, Leeds LS9 7TF, U.K. 3 To whom correspondence should be addressed (e-mail jbg20!medschl.cam.ac.uk).
wild-type and Val$$( variant enzymes respectively. The Val$$( mutant aldolase had an increased susceptibility to proteolytic cleavage in E. coli and rapidly lost activity on storage. Comparative CD determinations showed that the Val$$( protein had a distinct thermal denaturation profile with markedly decreased enthalpy, indicating that the mutant protein is partly unfolded. The undegraded mutant had preferentially decreased affinity and activity towards its specific F-1-P substrate and maintained appreciable activity towards FBP. In contrast, fluorescence studies of the mutant showed an increased binding affinity for products of the aldolase reaction, indicating a role for the Cterminus in mediating product release. These findings in a rare but widespread naturally occurring mutant implicate the Cterminus in the activity of human aldolase B towards its specific substrates and demonstrate its role in maintaining the overall stability of the enzyme tetramer.
Key words : catalytic defect, enzyme mutant, human gene. fructose 1,6-bisphosphate (FBP). Aldolase B is expressed selectively in tissues that metabolize exogenous fructose ; unlike the ubiquitous glycolytic A isoform, which is principally active towards FBP, it catalyses the breakdown of both substrates about equally. Approx. 98 % of the aldolase protein in normal human liver is aldolase B ; aldolase A accounts for the remainder. Determinations of fructaldolase activities in liver from patients with fructose intolerance show that FBP aldolase activity is usually decreased to 16-25 %, whereas the activity towards F-1-P is 0-10 % of control values [1, 8] . Several mutations in the human aldolase B gene have been identified in HFI [6, 9, 10] . Of these, the most predominant, Ala"%* Pro, Ala"(% Asp and Asn$$% Lys, have been shown to represent 65 %, 14% and 6 % of European HFI alleles [11] and 32 %, 11% and 2 % of North American alleles respectively [12] . Although it has been suggested that partial activity of mutant aldolase B might prevent the development of hypoglycaemia on fasting [13] , we have shown that null alleles of aldolase B are associated with HFI that is compatible with normal adult life, even in homozygotes, when strict dietary treatment is instituted [14, 15] .
We report here a novel mis-sense mutation in the aldolase B molecule that has been identified in patients with HFI and that as a recombinant protein expressed in Escherichia coli is uniquely informative about aldolase function and disease pathogenesis.
The presence of a conservative substitution in the C-terminal α-helical region of the enzyme selectively inactivates its intrinsic catalytic activity towards the specific F-1-P rather than the generic FBP substrate.
MATERIALS AND METHODS

Subjects
The proposita was the firstborn infant of maternal first cousins originating from Terçan, a province in eastern Turkey. The infant was given undiluted fruit juice at 6 weeks of age and was admitted to hospital because of vomiting and liver enlargement. Blood examination revealed an elevated glutamic-pyruvic transaminase activity (1680 i.u.\l ; normal activity less than 40 i.u.\l) and hypoglycaemia (blood glucose 1.8 mM, normal activity more than 3.5 mM). No deficiency of blood coagulation factors was identified and neither glucose nor amino acids were detected on urine analysis. An exclusion diet lacking galactose and fructose was instituted with accompanying clinical improvement (serum glutamic-pyruvic transaminase, 16 i.u.\l). Intravenous infusion of fructose (0.5 g\kg bodyweight) under controlled conditions induced hypoglycaemia, hypophosphataemia and hyperuricaemia, indicating fructose intolerance. A liver biopsy specimen was obtained for enzymic analysis : F-1-P aldolase activity was 0.08 µmol\min per g of tissue (normal 4-12) ; FBP aldolase activity was 1.96 µmol\min per g (normal [4] [5] [6] [7] [8] [9] [10] [11] [12] ; the activity ratio of FBP to F-1-P was 24.5 (normal ratio less than 2.0). When last reviewed at age 6 years, while taking the fructose exclusion diet supplemented with ascorbic acid and folic acid, the child was in good health with normal clinical and laboratory tests of liver function. Both parents remain healthy and have had two further children (see the Results section), both of whom are identically affected by fructose intolerance as demonstrated by restriction endonuclease digestion of amplified exons 9 of aldolase B genes with MscI. These analyses were conducted with genomic DNA extracted from umbilical cord blood samples taken immediately after birth. All the offspring are receiving a strict diet free of fructose, sorbitol and sucrose.
Materials
DNA-modifying enzymes, which include restriction endonucleases, T4 DNA ligase and the Klenow fragment of DNA polymerase 1, were purchased from Boehringer Mannheim or New England Biolabs. Taq polymerase was obtained from Promega. Pfu DNA polymerase was obtained from Stratagene. Oligonucleotides were obtained from either Pharmacia or Genosys corporations. Gelase was purchased from Epicentre Technologies (Cambridge, U.K.). The reagents used for radionucleotide-based DNA sequencing were from USB Corporation. Reagents for dye terminator sequencing where from Amersham. Adenosine 5h-[α-[$#S]thio]triphosphate was purchased from DuPont-NEN. The E. coli strains CJ236 and TG1 as well as the bacteriophages M13mp19 were from Promega. The E. coli strain BL21(DE3) was purchased from Stratagene. The pET-21(j) expression vector was purchased from NBL Gene Sciences. The protease inhibitors PMSF, leupeptin and pepstatin A were obtained from Boehringer Mannheim. The aldolase substrates F-1-P and FBP were purchased from Boehringer Mannheim and Sigma. Ampicillin and isopropyl β--thiogalactoside (IPTG) as well as other chemicals and reagents were of the highest grade available from Sigma Chemical Company. Cibacron Blue thiazine affinity chromatographic gel (Blue Sepharose affinity dye CL-6B), DEAE-Sepharose, desalting Sephadex PD-10, Mono-S and Superose 12 columns and resins were obtained from FP Pharmacia-LKB (Uppsala, Sweden).
Molecular analysis of the human aldolase B gene
Genomic DNA, prepared from EDTA-anti-coagulated peripheral blood [16] was used in PCR to amplify the eight exons encoding the human aldolase B polypeptide. The amplified fragments also included the splice-site junctions [9] . The amplified DNA sequences were purified from agarose gels by using Gelase before direct sequencing by means of the chain-termination procedure with Sequenase [17] . To confirm the presence of the Val$$( mutation identified in the amplified genomic products, freshly amplified exon 9 fragments were precipitated with ethanol and digested with the restriction endonuclease MscI in accordance with the manufacturer's instructions.
Construction of expression plasmid and oligonucleotide-directed mutagenesis
The truncated human aldolase B cDNA clone pHL413 [18] , which lacks the first 35 amino acid residues of the polypeptide, was excised as a partial PstI fragment and subcloned into the PstI site of pEMBL 18 to give pHAB413. At the same time, amplified exon 2 of wild-type human aldolase B [9] was cloned into the SmaI site of pEMBL19 to give pEE.PCR200. This plasmid was digested with NcoI, which cleaves the ATG translation initiation site of exon 2, and blunt-ended with the Klenow fragment of DNA polymerase ; the insert was excised as a 108 bp fragment with the endonuclease HinfI. The truncated aldolase B insert of pHAB413 was excised as an XbaI-partial HinfI fragment and the complete coding sequence was constructed by ligation of this fragment with the HinfI-NcoI (filled in) exon 2 sequence, into pEMBL19 that had been cleaved with SmaI and XbaI. The recombinant plasmid containing the desired sequence was termed pHABX1. The expression plasmid p∆XB, containing the wild-type human aldolase B cDNA, was created by excising the insert with the complete coding sequence of aldolase B from the plasmid pHABX1, as a HindIII-partial NcoI fragment and subcloned into the vector pKK∆4, which had been cut with the same two enzymes. The vector pKK∆4 is a deletion derivative of pKK233.2 [19] , which had been constructed after a double digestion with P uII and BamH1, filling in with the Klenow fragment and self-ligation.
The mutant plasmid pA337V was created by the Kunkel method for mutagenesis [20] . The wild-type aldolase B cDNA was cloned into the phage M13mp19 and grown in the CJ236 E. coli strain. A synthetic DNA oligonucleotide SDA337V (5h-GCTAACTGCCAGGTGGCCAAAGG-3h), spanning the region to be mutated, was annealed to the uracil-rich singlestranded template then extended and ligated to form heteroduplex molecules that were then transfected into E. coli strain TG1. Plaques that formed were analysed by single-stranded M13 DNA sequencing. A mutagenized M13 clone was subcloned into p∆XB by using the unique restriction endonuclease sites ApaI and HindIII to create the new aldolase B plasmid.
Expression of the wild-type and Val$$( variant of aldolase B was increased by subcloning the genes into the T7 promoter expression vector pET-21(j). The wild-type and Val$$( genes were amplified with Pfu DNA polymerase with the use of p∆XB and pA337V as templates and with the primers ER1 (5h-CGGATAACGAATTCATAAGGAGGAAACAG-3h) and HP (5h-GGAGCTAAGCTTGCGGGCA-3h). The ER1 primer introduces an EcoRI site upstream of the gene and also incorporates a modification of the parent flanking ribosome-binding site so that it includes a consensus E. coli ribosome-binding site [21] .
Inclusion of this primer also introduces an ATG initiation codon nine bases away from the ribosome-binding site and immediately upstream of the first Ala residue that is represented by the first codon of the human aldolase B polypeptide. The HP primer incorporates a unique HindIII site downstream of the human aldolase cDNA, thereby removing the poly(A) tail. The amplified products were cloned directionally into the expression vector pET-21(j), generating the plasmids designated pEBRj and pEBR337V, corresponding to the wild-type and Val$$( variant expression plasmids respectively. The structures of the plasmid inserts were confirmed by digestion with the restriction enzyme MscI and by DNA sequencing. No adventitious mutations were identified.
Bacterial expression of human aldolase B
The plasmid to be expressed was transformed into the proteasedeficient E. coli strain BL21(DE3). To obtain samples of enzyme exhibiting different physical conformations, recombinant aldolase B was expressed at either 37 or 22 mC. An overnight culture of the recombinant bacterial strain was used to inoculate 500 ml (for growth at 37 mC) or 250 ml (for growth at 22 mC) of ampicillin-supplemented 2YT medium and grown until D '!! reached 0.6-0.7. The gratuitous inducer IPTG was added to a final concentration of 1 mM, and the culture was incubated for a further 2.5 h when grown at 37 mC or for a further 16 h when grown at 22 mC. Bacteria in the induced culture were harvested by centrifugation and cells were resuspended in 15 ml of ice-cold 50 mM Tris\HCl\2.5 mM EDTA (pH 7.6)\5 mM dithiothreitol\5 % (v\v) glycerol\0.2 mM PMSF\20 µg\ml pepstatin A\20 µg\ml leupeptin. The cells were lysed by sonication and cell debris was removed by centrifugation at 30 000 g for 45 min at 4 mC.
Purification of aldolase B
Recombinant wild-type and Val$$( human aldolase B in the bacterial extracts were fractionated on DEAE-Sepharose, which retains acidic E. coli proteins. The unbound fraction was then adsorbed on Cibacron Blue Sepharose CL-6B affinity matrix. After application to the Cibacron Blue thiazine affinity matrix and washing with 50 mM Tris\HCl\10 mM EDTA (pH 7.6) buffer, the recombinant protein was affinity eluted with a pulse of 2-5 mM FBP in 50 mM Tris\HCl\5 mM EDTA (pH 8.6) [22] . The eluted proteins were concentrated with either an Amicon concentrator fitted with a YM30,000 filter or a Millipore ultrafree filter device (30 kDa cut-off). The concentrated proteins were then fractionated by gel filtration in an FPLC Superose 12 column in 50 mM Tris\HCl\100 mM NaCl. Val$$( protein expressed at 37 mC was then exchanged into 50 mM Mops, pH 7.0, with Sephadex PD-10 columns and bound to a Pharmacia Mono-S FPLC column ; protein fractions were eluted with an NaCl gradient. Approx. 50 % of the original wild-type and approx. 15 % of the Val$$( protein was recovered from cell lysates.
Electrophoresis and immunoblotting
Protein samples were subjected to electrophoresis through denaturing polyacrylamide gels containing SDS by the method of Laemmli [23] . The proteins were identified in the gel by staining with Coomassie Brilliant Blue G250. The differing proportions of intact mutant polypeptides fractionated in Coomassie Bluestained SDS\polyacrylamide gels were determined by laser densitometry. For immunoblotting, the gel was electroblotted to a PVDF filter for binding to a polyclonal sheep anti-(human aldolase B) antibody (Merck). Polypeptides reacting specifically with primary antibody were detected by sequential incubation with biotinylated mouse anti-sheep IgG followed by avidinalkaline phosphatase conjugate (Sigma Immunochemicals). Human aldolase B was finally identified by incubating the washed filter in tetrazolium substrate, which confirmed the exact location of the primary reaction between sheep antibody and the recombinant aldolase B polypeptides.
Assay for aldolase activity
The catalytic activities of aldolase B towards the substrates F-1-P (45 mM) and FBP (1 mM) were determined by measuring NADH oxidation at 340 nm with the method of Nakamura et al. [34] . Enzymic assays were conducted at 22 mC in a 1 ml volume by the addition of aldolase protein containing substrate, 0.15 mM NADH, 50 mM Tris\acetate, 10 mM EDTA, pH 7.6, 100 µg\ml BSA and 10 µl of α-glycerophosphate dehydrogenase\triose phosphate isomerase (2 mg\ml). One unit of activity is equivalent to the cleavage of 1 µmol of hexose substrate\min. The protein concentration of pure aldolase was determined spectroscopically by determining A #)! [25] and by using the bicinchoninic acid method (Pierce Chemical Co.). Kinetic estimates were determined in duplicate by least-squares analysis of at least three separate enzyme preparations by using the LEONORA program [26] .
Fluorescence measurements
Fluorescence measurements were made with a Perkin-Elmer LS 50B spectrofluorimeter. The intrinsic fluorescence of aldolase B was measured in 50 mM Tris\acetate\10 mM EDTA (pH 7.6) at 25 mC with an excitation wavelength of 295 nm and emission wavelengths of 325-365 nm. Triose ligands were added sequentially and the quenching of fluorescence was estimated by the decrease in peak intensity. Optimal emission was controlled by varying the emission slit widths between 5 and 10 nm. A 0.5 ml cuvette with a pathlength of 1 cm along the excitation axis and 0.2 cm along the emission axis was used for the analysis. Binding constants were derived by using the GRAFIT equationfitting program (Erithracus Software Ltd) and are expressed meanspS.E.M.
CD studies
CD measurements were made with a JASCO J-720 spectropolarimeter. CD spectra of samples were collected with a 0.05 cm pathlength quartz cuvette at a protein concentration of 0.25 mg\ml in 50 mM phosphate buffer, pH 7.4. Changes in the secondary structure of aldolase with time and temperature were measured by monitoring the CD signal at 222 nm. The effects of thermal unfolding on ellipticity were determined at a rate of 60 mC\h in 0.1 mC increments. The results were used to calculate the inflection point of the transition and the melting temperature, T m , by using the formulation defined by Lawrence et al. [27] and plotted with GRAFIT (see above).
RESULTS
Identification of the aldolase B mutation
Genomic DNA obtained from leucocytes in peripheral blood drawn from the 4-year-old proposita was analysed for the presence of mutations in the human aldolase B gene. Molecular analysis excluded the presence of the common mis-sense alleles Ala"%* Pro and Ala"(% Asp [10] ; however, allele-specific oligonucleotide hybridization for the mutation Asn$$% Lys [28] failed to show selective hybridization with either the wild-type or the mutant oligonucleotides after discriminatory washing at 57 mC (results not shown). The Asn$$% oligonucleotide primers span a 16 bp sequence of DNA encompassing the Asn$$% Lys, G C transversion. The absence of hybridization at the discriminatory temperature suggested the presence of a mutation within the amplified region of exon 9 in the vicinity of the Asn$$% Lys site but not Asn$$% Lys itself. The nature of this putative mutation was investigated by a sequence analysis of exon 9 ( Figure 1A) . Sequencing of exon 9 of aldolase B from the proposita showed a C T transition for the first base of codon 337, which would result in the replacement of an alanine residue by a valine, hence the designation Val$$(. This mis-sense mutation generates a new recognition sequence for the restriction endonuclease MscI (TGG CCA), thus facilitating confirmation of the presence of the allele in the proposita and her immediate family members. Complete digestion of the amplified 205 bp fragment containing exon 9 with the enzyme MscI resulted in two fragments of 111 and 94 bp by using DNA obtained from the proposita, indicating that she was homozygous for the mutation ( Figure 1B) . As expected, a comparable analysis of her parents showed partial cleavage of the 205 bp fragment after MscI digestion, indicating that they were heterozygous for the Val$$( mutation. Similar analyses of two subsequent live-born siblings of the proposita have confirmed homozygosity for the Val$$( mutant allele. All three siblings remain well after the institution of a strict fructose exclusion diet.
Similar analyses of a Finnish patient with HFI and a Swiss patient with this disorder has revealed the presence of the Val$$( mutant allele in compound heterozygous form with the Ala"%* Pro allele [6] .
Analysis of recombinant human aldolase B
Mendelian segregation of Val$$( in association with HFI and its independent association with the disease phenotype in individuals harbouring an additional aldolase B mutation indicated that the conservative replacement of an alanine residue by valine at position 337 leads to the pathological inactivation of the enzyme molecule. To investigate the precise effects of this mutation on catalytic function, these human aldolases were expressed in E. coli. Bacterial expression of the recombinant proteins was tightly regulated and is driven by the highly processive T7 DNA polymerase enzyme on induction.
The expression plasmid encoding wild-type human aldolase B conferred abundant F-1-P and FBP aldolase-splitting activity, comparable to that possessed by purified aldolase B obtained from human liver [25, 29] and human liver supernatant extracts ( Figure 2 and Table 1 ), indicating that the addition of an Nterminal methionine residue to the recombinant enzyme did not detectably affect the activity of the enzyme. SDS\PAGE analysis of bacterial lysates and purified aldolase preparations under denaturing conditions showed the expected 38 kDa species corresponding to the aldolase B subunit polypeptide. Densitometric scanning estimates and substrate cleavage estimates indicated that the recombinant enzyme accounted for approx. 30 % of the soluble protein fraction in the bacterial extracts bearing the wild-type aldolase B expression plasmid. It is noteworthy that the 38 kDa polypeptide was absent from bacterial lysates prepared with the non-recombinant vector (results not shown). A Western blot analysis with polyclonal anti-(human aldolase B) antibody was undertaken to determine whether the additional 38 kDa species in the extracts of E. coli transformed with the recombinant plasmids corresponded to polypeptides with aldolase B immunoreactivity. As expected, the 38 kDa species that was derived from the recombinant expression plasmids encoding the human aldolases reacted specifically with the antibody. No protein species bound antibody in the vector only and untransformed bacterial control extracts (results not shown).
The purified aldolase preparations were assayed for fructaldolase activities to obtain values for the specific activities, K m values and substrate activity ratios (V FBP max \V F-"-P max ). Purified wild-type recombinant human aldolase B gave specific activities, K m values and substrate activity ratios similar those to the purified enzyme obtained from human liver [25, 29] (Table 1) .
The purification strategy initially adopted for the Val$$( aldolase B variant utilized expression at 37 mC, lysis, anion-
A
Figure 2 Purification of the wild type and the Val 337 variant of human aldolase B expressed as a recombinant protein in bacteria
After transformation of the protease-deficient BL21(DE3) E. coli strain, with the modified expression plasmids pEBRj and pEBR337V respectively, and induction by the addition of 1 mM IPTG, the cells were harvested and lysed as described in the Materials and methods section. Aldolase B was purified from bacterial supernatants by using thiazine dye affinity chromatography and substrate elution as described [22] . (A) Recombinant proteins stained with Coomassie Blue G250 after separation by SDS/PAGE under denaturing conditions as described by Laemmli [23] exchange affinity chromatography followed by gel filtration. This procedure generated mixed populations of Val$$( enzyme with a decreased content of the 38 kDa polypeptide species and included two smaller polypeptides at apparent molecular masses of 36 and 33 kDa (results not shown). These smaller species were taken to represent truncated variants of the Val$$( peptide because West- ern blot analysis with polyclonal anti-(human aldolase B) antibody confirmed that the 38 kDa species and the two additional polypeptides of 36 and 33 kDa reacted strongly. The aberrant species comprised 22 % and 43 % respectively of the recombinant products. These findings suggested that the Val$$( variant polypeptide, unlike wild-type aldolase B, is highly susceptible to limited proteolytic cleavage in E. coli. The recombinant Val$$( variant aldolase B purified after expression and growth at 37 mC had lower specific activities than the wild type. There was also a marked decrease in activity towards the F-1-P substrate and an appreciable retention of catalytic activity towards the general fructaldolase substrate FBP so that the substrate activity ratio was 5. Unlike wild-type aldolase B, the recombinant Val$$( protein was also unstable when stored on ice or when subjected to a single episode of freeze-thawing, indicating a tendency to denature (Table 1) .
Native Val$$( protein was purified from bacterial cultures that were grown for expression of recombinant enzyme at 22 mC. The mutant protein was isolated rapidly in a pure undegraded form by anion-exchange affinity elution from thiazine dye resins ; the final resolution from impurities was achieved by gel filtration. Native Val$$( protein was isolated with catalytic activities as shown in Table 1 . Val$$( was highly active with respect to FBP with a specific activity very similar to that of wild-type enzyme preparations. The maximal activity of Val$$( towards F-1-P was 58 % of wild type but the intact protein had K m values that were 10-fold those of wild type, indicating that the affinity for the specific aldolase B substrate was markedly impaired. The catalytic properties of the intact and truncated variants of the Val$$( protein differed only slightly. This indicates that the predisposition of Val$$( homozygotes towards fructose intolerance is attributable to the aberrant catalytic properties of the mutant enzyme and not solely to its tendency to denature.
The affinity of the Val$$( protein for its triose substrates\ products was examined by quenching of intrinsic fluorescence ( Table 2 ). In the absence of triose, the maximum emission
Figure 3 CD measurements of recombinant human aldolases B
Ellipticity determinations at 222 nm of the wild-type (WT) and Val 337 (A337V) proteins in relation to temperature were made at intervals of 0.1 min, as described in the Materials and methods section. The curves depict the best-fit analyses of each denaturation profile (see Table 3 ) [27] . wavelength, λ max , of the mutant protein was 340 nm compared with the wild-type aldolase B λ max of 330 nm (results not shown).
Triose binding studies showed a greater than 10-fold increase in apparent affinity for both triose substrates, including the aldolase B-specific substrate, -glyceraldehyde, derived from the cleavage of F-1-P. The effects of the Val$$( substitution on aldolase B conformation were examined by determining the influence of temperature on CD measurement at 222 nm on mutant and wildtype proteins (Figure 3) . The Val$$( protein exhibited a distinct, flattened ellipticity profile during thermal denaturation ; the markedly smaller slope reflects an abnormal α-helical structure and decreased enthalpy (Table 3 ) [27] .
DISCUSSION
Here we report studies of a hitherto uncharacterized natural mutant of human aldolase B associated with HFI. The novel mutant allele occurred in three independent geographical isolates : it was originally identified in a homozygous form in the offspring of a consanguineous marriage in Turkey and has since been identified in patients with HFI from Switzerland and from Finland. This shows that, although rare, the mis-sense mutation is widespread in the human population.
The recombinant Val$$( aldolase B has distinct structural and kinetic characteristics. When expressed in E. coli at 37 mC, the variant formed tetramers consisting of varying proportions of individual truncated subunits. Importantly, the native Val$$( homotetramer exhibits an increased K m for its specific F-1-P substrate while retaining an affinity for FBP resembling that of the wild type. This demonstrates that the invariant alanine residue at position 337 is required for the isoenzyme-specific activity of the enzyme towards its alternative fructose phosphoester substrates.
The class 1 aldolases possess a three-dimensional polypeptide backbone fold that corresponds to an α\β-barrel structure [30] . The alanine residue at position 337, which is located at one pole of the α-helical stretch of the C-terminal sequence, is invariant in all mammalian class 1 aldolases, irrespective of isoenzyme type. An alanine residue at this position is also found in plant aldolases, including those of spinach, rice, legumes and Arabidopsis as well as in the glycosomal aldolase of the protozoan Trypanosoma brucei ( [31] [32] [33] [34] [35] , and EMBL database accession number X89829). The Val$$( substitution is located in an α-helix (residues 320-339) that precedes the conformationally flexible C-terminus ( [30] , and J. Sygusch, unpublished work). The presence of even an additional methyl group on the valine side chain is likely to disrupt the tight attachment between terminal helices and by causing misalignment induced partial denaturation of the human protein (J. Sygusch, unpublished work).
This proposition is confirmed by the abnormal intrinsic fluorescence and CD measurements of the Val$$( aldolase B : the protein has a greatly altered thermal denaturation profile with reduced enthalpy that indicates a significant disruption of its secondary structure. The marked shift of the fluorescence towards longer wavelength maxima suggests that at least one of the three tryptophan residues (at positions 147, 294 and 312) in the mutant protein is more exposed to solvent than in the wild type.
The catalytic properties of the Val$$( protein are consistent with the suspected involvement of the C-terminus in modulating the substrate specificity of the human aldolase B isoenzyme. The sequence of the C-terminal 30 residues of type I aldolases is highly variable, whereas the active-site residues are invariant [30, 36, 37] . Thus the C-terminus might confer the specific substrate activities that correspond to the functional differentiation of the fructaldolases [30] . A recognition of the influence of the Cterminus on substrate specificity has emerged from studies of carboxypeptidase treatment and artificial mutagenesis [36, 38, 39] .
The established role of the C-terminus involves the protonation of the enzyme-dihydroxyacetone phosphate complex, which is the limiting catalytic step for the A isoform of aldolase [40] . Kinetic studies of both carboxypeptidase-treated enzymes show that the release of dihydroxyacetone phosphate is affected [40, 41] . Mutagenesis and kinetic studies of the nine penultimate, Cterminal residues of the maize aldolase indicates that the primary effect of each point mutation is purely kinetic, affecting the attachment or release of substrate or product from the enzyme [39] . Some mutants of maize aldolase that extend the C-terminus arm seem to be defective in the release of -glyceraldehyde 3-phosphate. Hence residues present at positions 346 and 349 perturb the interaction of the C-6 phosphate-binding locus of the enzyme with substrate and\or product, modulating F-1-P\FBP discrimination. Thus the role of the C-terminus is not limited to proton exchange. The C-terminus is tightly associated with the active site in conformations that are probably unfavourable for efficient catalysis so that the limiting step in aldolase B catalysis is product release [39, 42] . This is clearly illustrated with the Val$$( human B isoenzyme : studies of fluorescence quenching induced by triose quenching indicate a greatly increased binding affinity for triose products, as predicted for a C-terminal mutant. Structural analysis of the rabbit liver aldolase shows that -glyceraldehyde 3-phosphate is released by a concerted conformational transition of the entire subunit including the Cterminus. Once expelled, the C-terminus is free to interact with the enzyme-dihydroxyacetone phosphate complex in protonation\proton abstraction. Val$$( is unable to clear the triose products efficiently ; this includes the specific -glyceraldehyde product of F-1-P cleavage.
Val$$( is more prone to proteolysis in E. coli when expressed at 37 mC, a finding compatible with partial denaturation of the Cterminus. Proteolytic degradation in i o might contribute to the catalytic deficiency of aldolase B in the liver but it is unlikely to account for all the characteristics of the Val$$( protein. Treatment of liver aldolase with carboxypeptidase decreases the activity towards both hexose substrates by approx. 50 % [40, 42] ; starvation-induced proteolysis of liver aldolase in mice, which also cleaves C-terminal residues, shows no selective effects on F-1-P activity [43] . Although the partly denatured Val$$( protein might be degraded more rapidly in i o compared with the wildtype enzyme, this would not explain the loss of function specific to aldolase B.
In HFI, kinetic studies have consistently shown a decreased affinity for the specific substrate F-1-P, even in tissues where there was appreciable residual aldolase activity [8, 29, 44] . Here the catalytic properties of the purified recombinant Val$$( variant aldolase, with its substrate activity ratio approaching 2 : 1 for FBP to F-1-P (5 : 1 for stored enzyme), resemble the enzymic activities determined in situ in the proposita, who was homozygous for the mutation. Although the presence of constitutive aldolase A might account partly for the substrate activity ratios observed in HFI liver samples, the presence of abundant residual FBP aldolase-splitting activity of the Val$$( enzyme does not prevent symptoms. Impaired cleavage of F-1-P in the specialized fructose pathway is therefore pathogenic. We have previously reported that patients with HFI who are homozygous for null alleles of aldolase B [14] remain asymptomatic while they abstain from fructose. The selective inability to cleave the F-1-P substrate derived from dietary fructose and cognate sugars is therefore necessary and sufficient for the development of hypoglycaemia and other manifestations of this disease.
